

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI: Cohort definition codes. Codes represented are ICD-10 codes for diagnoses, LOINC codes for laboratory values and CPT codes for procedures.

Covid-19 infection		Covid-19 vaccination	
Inclusion criteria	Exclusion criteria	Inclusion criteria	Exclusion criteria
U07.1 COVID-19 J12.82 Pneumonia due to coronavirus disease 2019) (9088 SARS coronavirus 2 and related RNA [Presence] [Positive, ever] 94500-6 SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 94309-2 SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen by NAA with probe detection [Positive, ever] 94759-8 SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection [Positive, ever] OR 94565-9 SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection [Positive, ever] OR 94502-2 SARS-related coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 95608-6 SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with non-probe detection [Positive, ever] 94745-7 SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection [≤ 40 {Ct_value}, ever] 94845-5 SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by NAA with probe detection [Positive, ever] 95424-8 SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by Sequencing [Positive, ever] 95406-5 SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection [Positive, ever] 94819-0 SARS-CoV-2 (COVID-19) RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection [≥ 0.1 {Log_copies}/mL, ever] 94746-5 SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Specimen by NAA with probe detection [≤ 40 {Ct_value}, ever] (94558-4 SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay [Positive, ever] OR 95209-3 SARS-CoV+ SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay [Positive, ever] 96119-3 SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay [Positive, ever] OR 97097-0 SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay [Positive, ever] (9089 SARS coronavirus 2 IgG IgM Ab [Presence] in Serum or Plasma [Positive, ever] 94563-4 SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum or Plasma by Immunoassay [Positive, ever] OR 94559-2 SARS-CoV-2 (COVID-19)	1037838 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage 0173A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 0073A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose 0083A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose 0112A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose 0074A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose 0052A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose 1037332 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage 0013A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	1037838 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage 0173A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose 0073A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose 0083A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose 0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose 0112A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose 0074A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose 0052A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose 1037332 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage 0013A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose 0164A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	U07.1 COVID-19 J12.82 Pneumonia due to coronavirus disease 2019) (9088 SARS coronavirus 2 and related RNA [Presence] [Positive, ever] 94500-6 SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 94309-2 SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen by NAA with probe detection [Positive, ever] 94759-8 SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection [Positive, ever] OR 94565-9 SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection [Positive, ever] OR 94502-2 SARS-related coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 95608-6 SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 95406-5 SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection [Positive, ever] 94819-0 SARS-CoV-2 (COVID-19) RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection [≥ 0.1 {Log_copies}/mL, ever] 94746-5 SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Specimen by NAA with probe detection [≤ 40 {Ct_value}, ever] (94558-4 SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay [Positive, ever] OR 95209-3 SARS-CoV+ SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay [Positive, ever] 96119-3 SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay [Positive, ever] OR 97097-0 SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay [Positive, ever] (9089 SARS coronavirus 2 IgG IgM Ab [Presence] in Serum or Plasma [Positive, ever]

96763-8 SARS-CoV-2 (COVID-19) E gene [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 94314-2 SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Specimen by NAA with probe detection [Positive, ever] 96741-4 SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing [Unknown] SARS-CoV-2 Alpha variant (WHO) SARS-CoV-2 Beta variant (WHO) SARS-CoV-2 Delta variant (WHO) SARS-CoV-2 Gamma variant (WHO) SARS-CoV-2 Omicron variant (WHO), ever] 96123-5 SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Upper respiratory specimen by NAA with probe detection [Positive, ever] 94312-6 SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 [≤ 40 {Ct_value}, ever] 94757-2 SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N2 [Positive, ever] 94311-8 SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 [≤ 40 {Ct_value}, ever] 96603-6 SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by sVNT [Positive, ever] 95409-9 SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection [Positive, ever] 98734-7 SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Units/volume] in Serum or Plasma by Immunoassay [≥ 0.1 [IU]/mL, ever] 94511-3 SARS-CoV-2 (COVID-19) F1ab region [Cycle Threshold #] in Specimen by NAA with probe detection [≤ 40 {Ct_value}, ever] 94756-4 SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N1 [Positive, ever] 95521-1 SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory specimen by NAA with probe detection [≥ 0.1 {copies}/mL, ever] 94509-7 SARS-related coronavirus E gene [Cycle Threshold #] in Specimen by NAA with probe detection [≥ 0.1 {Ct_value}, ever]) Z00 Encounter for general examination without complaint, suspected or reported diagnosis	booster dose OR 0054A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose 90480 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and over 0003A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose 0154A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose 0124A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose 1036663 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage 0031A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose 1036660 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted 0051A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose 0001A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose 0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose 0011A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-	90480 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose 0094A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and over 0003A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose 0154A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose 0124A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose 1036663 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage 0031A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose 1036660 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted 0051A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose 0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose 0011A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	94641-8 SARS-CoV-2 (COVID-19) S gene [Presence] in Specimen by NAA with probe detection [Positive, ever] 94758-0 SARS-related coronavirus E gene [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 94308-4 SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 [Positive, ever] 96763-8 SARS-CoV-2 (COVID-19) E gene [Presence] in Respiratory specimen by NAA with probe detection [Positive, ever] 94314-2 SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Specimen by NAA with probe detection [Positive, ever] 96741-4 SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing [Unknown] SARS-CoV-2 Alpha variant (WHO) SARS-CoV-2 Beta variant (WHO) SARS-CoV-2 Delta variant (WHO) SARS-CoV-2 Gamma variant (WHO) SARS-CoV-2 Omicron variant (WHO), ever] 96123-5 SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Upper respiratory specimen by NAA with probe detection [Positive, ever] 94312-6 SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 [≤ 40 {Ct_value}, ever] 94757-2 SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N2 [Positive, ever] 94311-8 SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 [≤ 40 {Ct_value}, ever] 96603-6 SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by sVNT [Positive, ever] 95409-9 SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection [Positive, ever] 98734-7 SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Units/volume] in Serum or Plasma by Immunoassay [≥ 0.1 [IU]/mL, ever] 94511-3 SARS-CoV-2 (COVID-19) F1ab region [Cycle Threshold #] in Specimen by NAA with probe detection [≤ 40 {Ct_value}, ever] 94756-4 SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N1 [Positive, ever] 95521-1 SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory specimen by NAA with probe detection [≥ 0.1 {copies}/mL, ever] 94509-7 SARS-related coronavirus E gene [Cycle Threshold #] in Specimen by NAA with probe detection [≥ 0.1 {Ct_value}, ever])
---	--	---	--

	CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose 0012A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose 840534001 Administration of SARS-CoV-2 antigen vaccine 0004A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose	vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose 840534001 Administration of SARS-CoV-2 antigen vaccine 0004A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose Z00 Encounter for general examination without complaint, suspected or reported diagnosis	
--	--	--	--

Table SII. Matching variables and corresponding baseline characteristic codes (ICD10-CM, RxNorm, VA) for the primary analysis and sensitivity analyses S1-3, S5. In S4 only codes marked with an asterisk (*) were used due to larger cohort sizes.

Matching variable	Code (ICD10-CM, RxNorm, VA)
Age at Index*	-
White*	-
Female*	-
Black or African American*	-
Hispanic or Latino	-
Diseases of the musculoskeletal system and connective tissue	M00-M99
Endocrine, nutritional and metabolic diseases*	E00-E89
Diseases of the respiratory system*	J00-J99
Diseases of the genitourinary system	N00-N99
Diseases of the digestive system*	K00-K95
Diseases of the circulatory system*	I00-I99
Diseases of the nervous system	G00-G99
Injury, poisoning and certain other consequences of external causes	S00-T88
Mental, Behavioral and Neurodevelopmental disorders	F01-F99
Certain infectious and parasitic diseases	A00-B99
Neoplasms	C00-D49
Overweight and obesity*	E66
External causes of morbidity	V00-Y99
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	D50-D89
Nicotine dependence*	F17
Streptococcus, group A, as the cause of diseases classified elsewhere*	B95.0
Family history of diseases of the skin and subcutaneous tissue*	Z84.0
Non-steroidal anti-inflammatory drugs	MS102
Benzodiazepines	CN302
Betablockers	CV100
ACE inhibitors	CV800
Bupropion	42347
Terbinafine	37801
Hydroxychloroquine	5521
Lithium salts	CN750
Rituximab	121191
Pembrolizumab	1547545
Interferon beta-1a	75917
Chloroquine	2393

Nivolumab	1597876
Ipilimumab	1094833
Durvalumab	1919503
Atezolizumab	1792776
Interferon alfa-2b	5880
Cemiplimab	2058826
Avelumab	1875534
Dostarlimab	2539967